P120: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE PREVENTION OF VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
M Callaghan,
K Ataga,
L De Franceschi,
C Minniti,
N Balachandran,
D Imbs,
T Perretti,
J Ramos,
A Sostelly,
P Bartolucci
Affiliations
M Callaghan
1 Division of Pediatric Hematology/Oncology, Central Michigan University SOM, Children’s Hospital of Michigan, Detroit, MI, UNITED STATES
K Ataga
2 UTHSC Center for Sickle Cell Disease, Memphis, TN, UNITED STATES
L De Franceschi
3 Department of Medicine, University of Verona and AOUI Verona, Verona, ITALY
C Minniti
4 Albert Einstein College of Medicine, Bronx, New York, NY, UNITED STATES
N Balachandran
5 Roche Products Limited, Welwyn Garden City, UNITED KINGDOM
D Imbs
6 Certara, Inc., Paris, FRANCE
T Perretti
7 F. Hoffmann-La Roche Ltd, Basel, SWITZERLAND
J Ramos
8 Genentech Inc., South San Francisco, CA, UNITED STATES
A Sostelly
7 F. Hoffmann-La Roche Ltd, Basel, SWITZERLAND
P Bartolucci
9 University Paris-East Créteil, Sickle Cell Referral Center - UMGGR & IMRB, Laboratory of Excellence LABEX GRex, Créteil, FRANCE
